Dose Dependent Long-term In Vivo Remission of AML1/ETO Positive Acute Myeloid Leukemia with G-CSF

References

• Broxmeyer, M.E. (1995) "Role of cytokines in hematopoiesis", In: Aggarwal, B.B. and Puri, R.K., eds, Human Cytokines. Their Role in Disease and Therapy (Blackwell Scientific Publications, Cambridge, MA), pp 27–36.
   Google Scholar
• Sachs, L. (1987) "Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells", Nature 274, 535–538.
   Google Scholar
• Terpstra, W. and Lowenberg, B. (1997) "Application of myeloid growth factors in the treatment of acute myeloid leukemia", Leukemia 11, 315–327.
   PubMed Web of Science ®Google Scholar
• Schiffer, C.A. (1996) "Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia", Blood 88, 3675–3685.
   PubMed Web of Science ®Google Scholar
• Tamura, M., Orita, T. and Oheda, M. (1993) "Reduction of the leukemogenic potential of malignant murine leukemic cells by in vivo treatment with recombinant human granulocyte colony-stimulating factor", Leukemia Res. 17(7), 593–600.
   PubMed Web of Science ®Google Scholar
• Bassan, R., Rambaldi, A., Amaru, R., et al. (1994) "Unexpected remission of acute myeloid leukemia after GM-CSF", Br. J. Haematol. 87, 835–837.
   PubMed Web of Science ®Google Scholar
• Touw, I., Donath, J., Pouwels, K., et al. (1995) "Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro response to interleukin-5", Leukemia 8, 687–692.
   Google Scholar
• Da Silva, N., Meyer-Monard, S., Menot, M.-L., et al. (2000) "Functional G-CSF pathways in 48;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO", Hematol. J. 1, 316–328.
   PubMedGoogle Scholar
• Ferrara, F., Di Noto, R., Viola, A., et al. (1999) "Complete remission in acute myeloid leukemia with 48;21) following treatment with G-CSF: flow-cytometric analysis of in vivo and in vitro effects on cell maturation", Br. J. Haematol. 106, 520–522.
   PubMed Web of Science ®Google Scholar
• Grimwade, D., Walker, H., Oliver, F., et al. (1998) "The importance of diagnostic cytogenetics on outcome in AML analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Coucil adult and children's leukemia Working Parties", Blood 92, 2322–2333.
   PubMed Web of Science ®Google Scholar
• Warrell, R.P., Frankel, SR., Miller, W., et al. (1991) "Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid)", N. Engl. J. Med. 324, 1385–1393.
   PubMed Web of Science ®Google Scholar
• Downing, J.R. (1999) "The AML1-ETO chimeric transcription factor in acute myeloid leukemia: biology and clinical significance", Br. J. Haematol. 106, 296–308.
   PubMed Web of Science ®Google Scholar
• Nucifora, G. and Rowley, J. (1995) "AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukaemia", Blood 86, 1–14.
   PubMed Web of Science ®Google Scholar
• Slovak, M.L., Bedell, V., Popplewell, L., Arber, D.A., Schoch, C. and Slater, R. (2002) "21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an International Workshop", Genes Chromosomes Cancer 33, 379–394.
   PubMed Web of Science ®Google Scholar
• Mrozek, K., Prior, T.W., Edwards, C., et al. (2001) "Compari-son of cytogenetic and molecular genetic detection of t(8;21)(q22;q22) and inv(16)(p13;q22) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study", J. Clin. Oncol. 19, 2482–2492.
   PubMed Web of Science ®Google Scholar
• Andrieu, V, Radford-Weiss, I., Troussard, X., et al. (1996) "Molecular detection of 48;21) AML1-ETO in AML M1 /M2: correlation with cytogenetics, morphology and immuno-phenotype", Br. J. Haematol. 92, 855–865.
   PubMed Web of Science ®Google Scholar
• Nakamura, H., Kuriyama, K., Sadamori, N., et al. (1997) "Morphological subtyping of acute myeloid leukemia with maturation AML-M2: homogeneous pink-coloured cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21)", Leukemia 11, 651–655.
   PubMed Web of Science ®Google Scholar
• Nucifora, G., Dickstein, J.I., Torbenson, V, et al. (1994) "Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21)", Leukemia 8, 1533–1538.
   PubMed Web of Science ®Google Scholar
• Kila, K., Nakase, K., Miwa, H., et al. (1992) "Phenotypical characteristics of acute myeloid leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34", Blood 80, 470–477.
   PubMed Web of Science ®Google Scholar
• Baer, M.R., Stewart, C.C., Lawrence, D., et al. (1997) "Expression of the neural cell Adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)", Blood 90, 1643–1648.
   PubMed Web of Science ®Google Scholar
• Sarriera, J.E., Albitar, M., Estrov, Z., et al. (2001) "Comparison of outcome in acute myelogenous leukemia patients with translocation 48;21) found by standard cytogenetic analysis and patients with AML1 /ETO fusion transcript found only by PCR testing", Leukemia 15, 57–61.
   PubMed Web of Science ®Google Scholar
• Licht, J.D. (2001) "AML1 and the AML1-ETO fusion protein in the pathogenesis of 48;21) AML", Oncogene 20(40), 5660–5679.
   PubMed Web of Science ®Google Scholar
• Girald, S., Escudier, S., Kantarjian, H., et al. (1993) "Preliminary results of treatment with filgrastim for relapse of leukaemia and myelodysplasia after allogeneic bone marrow transplantation", N. Engl. J. Med. 329, 757–761.
   PubMed Web of Science ®Google Scholar
• Mulloy, J.C., Cammenga, J., MacKenzie, K.L., Berguido, F.J., Moore, M.A.S. and Nimer, S.D. (2002) "The AML1-ETO fusion protein promotes the expansion of human hemato-poietic stem cells", Blood 99, 15–23.
   PubMed Web of Science ®Google Scholar
• Postma, D.S. and Siafakas, N.M. (1998) "Management of COPD", European Respiratory Society, Monograph 7, Vol. 3, pp 264–277.
   Google Scholar
• Bodey, G.P., Buckley, M., Sathe, Y.S., et al. (1966) "Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia", Ann. Intern. Med. 64, 328–340.
   PubMed Web of Science ®Google Scholar
• Nelson, S., Daifuku, R. and Andresen, J. (1993) "Use of filgrastim in infectious diseases", In: Morstyn, G. and Dexter, TM., eds, Filgrastim in Clinical Practice (Marcel Dekker, New York), pp 253–266.
   Google Scholar
• Paul, R., Remes, K., Lakkala, T., et al. (1994) "Spontaneous remission in acute leukaemia", Br. J. Haematol. 86, 210–212.
   PubMed Web of Science ®Google Scholar
• Tzankof, A., Ludescher, C., Duba, H.C., et al. (2001) "Spontaneous remission in a secondary acute myelogenous leukemia following invasive pulmonary aspergillosis", Ann. Hematol. 80(7), 423–425.
   PubMed Web of Science ®Google Scholar
• Chen, Z., Wang, Y, Wang, W., Gong, J. and Xue, Y. (2002) "All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype", Chin. Med. J. 115, 58–61.
   PubMed Web of Science ®Google Scholar